Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.


Unmasking Adenosine: The Purinergic Signalling Molecule Critical to Arrhythmia Pathophysiology and Management


Arrhythmia & Electrophysiology Review 2019;8(4):240–8.

Ivabradine and AF: Coincidence, Correlation or a New Treatment?


Arrhythmia & Electrophysiology Review 2019;8(4):300–3.

Improving Cardiac Resynchronisation Therapy


Arrhythmia & Electrophysiology Review 2019;8(3):220–7.

Monomorphic Ventricular Arrhythmias in Athletes


Arrhythmia & Electrophysiology Review 2019;8(2):83–9.